Key facts
- This page summarizes Gabriel Cohn's Form 4 filing for Homology Medicines, Inc. (QTTB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Jan 2022, 15:05.
Gabriel Cohn - 01 Jan 2022 Form 4 Insider Report for Homology Medicines, Inc. (QTTB)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- QTTB
- Reported as of
- 01 Jan 2022
- Net transaction value
- -$6,279
- Reporting owner signature
- /s/ W. Bradford Smith, Attorney-in-Fact for Gabriel Cohn
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Gabriel Cohn filed Form 4 for Homology Medicines, Inc. (QTTB) on 12 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$6,279.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FIXX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +4,290
- Change %
- Price
- Shares after
- 4,290
- Date
- 01 Jan 2022
- Ownership
- Direct
- Footnotes
- F1
FIXX
transaction
Common Stock
Sale
- Transaction value
- $6,279
- Shares
- -1,661
- Change %
- -39%
- Price
- $3.78
- Shares after
- 2,629
- Date
- 05 Jan 2022
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FIXX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -4,290
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 8,710
- Date
- 01 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,290
- Exercise price
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
Footnote F2
The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of RSUs.
Footnote F3
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $3.78 to $3.79. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3.
Footnote F4
The RSUs have vested and settled or will vest and settle, as applicable, as to one third of the restricted stock units on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date.